SecBot SecBot
S-3 ·Filed Aug 17, 2026

INDP

Indaptus Therapeutics, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001493152-26-038780
Shelf registration, potential dilution
Actionable Insight ▼ Bearish

The massive registration of 44.2% of shares outstanding creates severe overhang risk. Monitor for selling stockholder filings (Form 144) and any 424B prospectus supplements indicating actual sales. The company's cash burn and lack of pipeline make further dilutive financing likely, compounding the overhang.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.9361
T+0 close · Aug 17, 2026 · via day close
Latest settled
+242.91%
T+60 · $3.21
Vs SPY
+243.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $0.9361entry
  2. T+1 · 3mo ago +0.42%α +0.21% · $0.9400
  3. T+5 · 3mo ago +16.97%α +17.18% · $1.10
  4. T+20 · 2mo ago +242.91%α +244.22% · $3.21
  5. T+60 · 6d ago +242.91%α +243.91% · $3.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Indaptus Therapeutics filed an S-3 registration statement to register 58,895,000 shares of common stock for resale by selling stockholders, representing ~44.2% of shares outstanding. The company has no active clinical programs, having discontinued its Decoy20 study, and is evaluating strategic alternatives. The filing itself raises no new capital for the company but creates massive potential overhang from the selling stockholders, who can sell into the market at any time.

Key Facts

  • Registers 58,895,000 shares for resale by selling stockholders, representing ~44.2% of 133,242,324 shares outstanding.
  • No new capital raised for the company; all proceeds go to selling stockholders.
  • Company has discontinued all clinical programs (Decoy20) and has no active development pipeline.
  • Auditor's report includes a going concern explanatory paragraph.
  • Sino Lion Ventures Limited, a 29.19% holder, is registering 38,895,000 shares from converted preferred stock.
  • Seven other non-U.S. investors are registering 20,000,000 shares from a June 2026 private placement at $0.60/share.
  • Stock closed at $1.07 on August 14, 2026, the last trading day before filing.

Financial Impact

Potential overhang of ~$63M at $1.07/share from 58.9M registered shares, representing 44.2% of outstanding shares. The company's cash and short-term investments totaled $11.6M as of June 30, 2026.

dilutionmarket capliquidity

Risk Factors

  • Massive share overhang from 58.9M registered shares could crush the stock price if selling stockholders begin selling.
  • Company has no active clinical programs and is burning cash with a going concern warning.
  • Further dilutive financing is likely given the company's cash position and lack of revenue.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001493152-26-038780
Exhibit: ex107.htm0001493152-26-038780
Exhibit: ex5-1.htm0001493152-26-038780
Exhibit: ex23-2.htm0001493152-26-038780
Document: 0001493152-26-038780-index-headers.html0001493152-26-038780
Document: 0001493152-26-038780-index.html0001493152-26-038780
Document: 0001493152-26-038780.txt0001493152-26-038780

Track record

20 reports on INDP

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
  2. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  3. Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  4. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  5. Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
  6. Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
  8. Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
  9. Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
  10. Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026